AstraZeneca has announced a global ambition to launch 20 new medicines and almost double its revenue by the end of this decade.
The company said the plan to deliver US$80 billion in total revenue by 2030, up from US$45.8 billion in 2023, would be achieved through significant growth in its existing oncology, biopharmaceuticals and rare disease portfolio.
CEO Pascal Soriot said, “Today AstraZeneca announces a new era of growth. In 2023, we delivered the ambitious $45 billion revenue goal set a decade ago. With the exciting growth of our innovative pipeline, which has the potential to transform millions of lives, we are now aiming for $80 billion by 2030.
"We are planning to launch 20 new medicines by 2030, many with the potential to generate more than $5 billion in peak year revenues. The breadth of our portfolio together with continued investment in innovation supports sustained growth well past the end of the decade.”
The company also committed to decoupling its carbon emissions from its revenue increase. It said it has already reduced its greenhouse gas emissions (Scopes 1 and 2) by 68 per cent from its 2015 baseline while growing total revenue by 85 per cent. It said that by 2026, it will be carbon zero for Scope 1 and 2 emissions and, by 2030, halve its Scope 3 emissions.
